Wellington Management Group’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-107,262
| Closed | -$2.16M | – | 2005 |
|
|
2026
Q1 | $2.16M | Sell |
107,262
-15,117
| -12% | -$244K | ﹤0.01% | 1536 |
|
|
2025
Q4 | $1.98M | Sell |
122,379
-3,673
| -3% | -$48.6K | ﹤0.01% | 1605 |
|
|
2025
Q3 | $1.54M | Sell |
126,052
-6,848
| -5% | -$94.6K | ﹤0.01% | 1699 |
|
|
2025
Q2 | $1.5M | Buy |
132,900
+6,632
| +5% | +$81.1K | ﹤0.01% | 1641 |
|
|
2025
Q1 | $1.46M | Buy |
126,268
+3,405
| +3% | +$34.8K | ﹤0.01% | 1624 |
|
|
2024
Q4 | $1.04M | Buy |
122,863
+4,940
| +4% | +$51.2K | ﹤0.01% | 1709 |
|
|
2024
Q3 | $1.37M | Buy |
117,923
+33,900
| +40% | +$426K | ﹤0.01% | 1655 |
|
|
2024
Q2 | $990K | Buy |
84,023
+4,658
| +6% | +$54.4K | ﹤0.01% | 1680 |
|
|
2024
Q1 | $941K | Buy |
+79,365
| New | +$1.06M | ﹤0.01% | 1699 |
|
|
2022
Q4 | – | Sell |
-776,510
| Closed | -$11.3M | – | 2052 |
|
|
2022
Q3 | $11.3M | Buy |
776,510
+306,377
| +65% | +$4.28M | ﹤0.01% | 1075 |
|
|
2022
Q2 | $4.63M | Sell |
470,133
-876,609
| -65% | -$9.67M | ﹤0.01% | 1350 |
|
|
2022
Q1 | $19.9M | Sell |
1,346,742
-464,763
| -26% | -$6.68M | ﹤0.01% | 1019 |
|
|
2021
Q4 | $24M | Sell |
1,811,505
-19,936
| -1% | -$317K | ﹤0.01% | 1038 |
|
|
2021
Q3 | $32M | Buy |
1,831,441
+36,923
| +2% | +$748K | 0.01% | 950 |
|
|
2021
Q2 | $43M | Buy |
1,794,518
+285,493
| +19% | +$7.47M | 0.01% | 869 |
|
|
2021
Q1 | $38.8M | Buy |
1,509,025
+636,369
| +73% | +$16.7M | 0.01% | 886 |
|
|
2020
Q4 | $16.6M | Buy |
872,656
+108,697
| +14% | +$1.86M | ﹤0.01% | 1079 |
|
|
2020
Q3 | $9.62M | Buy |
763,959
+561,000
| +276% | +$7.01M | ﹤0.01% | 1111 |
|
|
2020
Q2 | $2.46M | Buy |
202,959
+3,644
| +2% | +$38.8K | ﹤0.01% | 1322 |
|
|
2020
Q1 | $1.52M | Sell |
199,315
-17,773
| -8% | -$240K | ﹤0.01% | 1418 |
|
|
2019
Q4 | $3.87M | Buy |
217,088
+191,019
| +733% | +$2.49M | ﹤0.01% | 1386 |
|
|
2019
Q3 | $303K | Buy |
+26,069
| New | +$421K | ﹤0.01% | 1949 |
|
Other funds holding KALV
Wellington Management Group's KALV Position: Q2 2026 in Review
Wellington Management Group sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 107,262 shares — an estimated $2.16M sold.
Wellington Management Group first reported a position in KALV in Q3 2019 and held it in 22 quarters. The position peaked at $43M in Q2 2021. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Wellington Management Group reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Wellington Management Group sold 107,262 KalVista Pharmaceuticals shares in Q2 2026, an estimated $2.16M.
- Wellington Management Group first reported a position in KalVista Pharmaceuticals in Q3 2019 and held it in 22 quarters.
- Wellington Management Group's KalVista Pharmaceuticals position peaked at $43M in Q2 2021.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.